A
Adaptyx Biosciences
Biowearable patch for continuous multi-analyte molecular monitoring
About Adaptyx Biosciences
Adaptyx Biosciences, founded in 2022, is a biowearables company that spun out of over a decade of research at Stanford University and the Chan Zuckerberg Biohub. The founders include CEO Vijit Sabnis, Ph.D., and Chief Science Officer Alex Yoshikawa, Ph.D., who developed the technology during his doctoral studies in Chemical Engineering at Stanford. The company is headquartered in Menlo Park, California.
The firm is developing a biowearable platform for continuous, multi-analyte molecular monitoring. The core technology consists of a minimally invasive microneedle sensor patch that uses programmable, synthetic DNA-based molecular switches. These lab-made DNA bioreceptors are engineered to bind to specific target molecules with high sensitivity, undergoing a reversible structural change upon recognition. This mechanism allows for the real-time, continuous tracking of a wide array of biomarkers in the interstitial fluid, moving beyond glucose to include hormones, proteins, electrolytes, and drugs. By combining this molecular sensing with AI-powered analytics, the platform aims to convert data streams into actionable insights for patients and clinicians, enabling earlier detection of health trends and more timely interventions.
To accelerate the development of new biosensors, Adaptyx operates a "Molecular Switch Foundry" which integrates automated molecular design, parallelized screening, and AI-driven optimization, significantly reducing development timelines. The company's business model is focused on obtaining FDA clearance for initial clinical applications, with future plans to expand into broader health and wellness markets. Current applications in development include heart failure management, hormone optimization for fertility and endocrine health, critical care drug monitoring, and personalized wellness tracking. The company makes money by developing and commercializing this platform for various healthcare segments.
Adaptyx Biosciences has secured a total of $23 million in funding since its inception. A recent seed financing round raised $14 million, led by Interlagos with significant participation from Overwater Ventures, Starbloom Capital, Stanford University, and the Chan Zuckerberg Biohub, among others. This capital is intended to accelerate research and development, expand the pipeline of molecular switches, support clinical trials, and scale the company's team.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 84.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotechnology, Biomarkers, Chronic Disease, Health Diagnostics, Spinout, Wearable, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Oct 2025 | $14M | $56M | Cantos Ventures · Interlagos Capital · Chan Zuckerberg Biohub · Overwater Ventures | ↗ |
| SPINOUT✓Other financing | Jan 2022 | $0 | — | Stanford University | — |
Growth signals
Latest recorded traffic for Adaptyx Biosciences is 6.9K monthly website visits, up 392.9% over the last three months. Adaptyx Biosciences's team grew 90% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Adaptyx Biosciences in the Menlo Park ecosystem
The Adaptyx Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed9 investors entered at this stage
Interlagos Capital
Cantos Ventures
Chan Zuckerberg Biohub
Overwater Ventures
Starbloom Capital
Seaside Ventures
Humba Ventures
Stanford University
Hyperlink Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adaptyx Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adaptyx Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









